Non-peptide vasopressin V1b receptor antagonists as potential drugs for the treatment of stress-related disorders

Current Pharmaceutical Design

Volumn 11, Issue 12, 2005, Pages 1549-1559

  Griebel, Guy ^a   Stemmelin, Jeanne ^a   Gal, Claudine Serradeil Le ^a   Soubrié, Philippe ^a  

^a SANOFI   (France)

Author keywords

Antidepressant; Anxiety; Anxiolytic; Depression; SSR149415; Stress; V1b receptor; Vasopressin

Indexed keywords

1 [5 CHLORO 1 (2,4 DIMETHOXYLPHENYLSULFONYL) 2,3 DIHYDRO 3 (2 METHOXYPHENYL) 2 OXO 1H INDOL 3 YL] 4 HYDROXY N,N DIMETHYL 2 PYRROLIDINECARBOXAMIDE; 1 [5 CHLORO 1 [(2,4 DIMETHOXYLPHENYL)SULFONYL] 3 (2 METHOXYPHENYL) 2 OXO 2,3 DIHYDRO 1H INDOL 3 YL] 4 HYDROXY N,N DIMETHYL 2 PYRROLIDINE CARBOXAMIDE; 4 (2 CHLORO 4 METHOXY 5 METHYLPHENYL) N [2 CYCLOPROPYL 1 (3 FLUORO 4 METHYLPHENYL)ETHYL] 5 METHYL N (2 PROPYNYL) 2 THIAZOLAMINE; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; BENZODIAZEPINE DERIVATIVE; CORTICOTROPIN; CORTICOTROPIN RELEASING FACTOR; CORTICOTROPIN RELEASING FACTOR ANTAGONIST; DIAZEPAM; FLUOXETINE; IMIPRAMINE; MONOAMINE OXIDASE INHIBITOR; NORADRENALIN; SAREDUTANT; UNCLASSIFIED DRUG; VASOPRESSIN; VASOPRESSIN RECEPTOR ANTAGONIST; VASOPRESSIN V1 RECEPTOR; VASOPRESSIN V1B RECEPTOR;

AGGRESSIVENESS; ANIMAL BEHAVIOR; ANXIETY DISORDER; ATAXIA; ATTENUATION; AUTONOMIC NERVOUS SYSTEM FUNCTION; COGNITIVE DEFECT; CORTICOTROPIN RELEASE; DEPRESSION; DRUG ANALYSIS; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERANCE; EMOTIONALITY; HORMONE INHIBITION; HYPERTHERMIA; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; HYPOTHESIS; MOTOR DYSFUNCTION; MUSCLE RELAXATION; NEUROENDOCRINE SYSTEM; NONHUMAN; NORADRENALIN RELEASE; PRIORITY JOURNAL; RELIABILITY; REVIEW; SEDATION; TRANQUILIZING ACTIVITY;

AGGRESSION; ANIMALS; ANTIDEPRESSIVE AGENTS; ANXIETY; BEHAVIOR, ANIMAL; DEPRESSION; DISEASE MODELS, ANIMAL; HUMANS; INDOLES; PYRROLIDINES; RATS; RECEPTORS, VASOPRESSIN;

EID: 18844443670     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612053764797     Document Type: Review

References (87)

1. Jenck F, Ouagazzal AM, Pauly-Evers M, Moreau JL. Orphanin FQ: role in behavioral fear responses and vulnerability to stress? Mol Psychiatr 2000; 5: 572-74.
2. Bale TL, Davis AM, Auger AP, Dorsa DM, McCarthy MM. CNS region-specific oxytocin receptor expression: Importance in regulation of anxiety and sex behavior. J Neurosci 2001; 21: 2546-52.
3. Griebel G. Is there a future for neuropeptide receptor ligands in the treatment of anxiety disorders? Pharmacol Ther 1999; 82: 1-61.
4. Aguilera G, Rabadan-Diehl C. Vasopressinergic regulation of the hypothalamic-pituitary-adrenal axis: implications for stress adaptation. Regul Pept 2000; 96: 23-29.
5. 1b Receptor Antagonist. J Pharmacol Exp Ther 2002; 300:1122-30.
6. van Leeuwen FW, Swaab DF, de Raay C. Immunoelectron-microscopic localization of vasopressin in the rat suprachiasmatic nucleus. Cell Tissue Res 1978; 193: 1-10.
7. Swanson LW, Sawchenko PE. Hypothalamic integration: organization of the paraventricular and supraoptic nuclei. Annu Rev Neurosci 1983; 6: 269-324.
8. Kurose T, Ueta Y, Nomura M, Yamaguchi K, Nagata S. Nociceptive stimulation increases NO synthase mRNA and vasopressin heteronuclearRNA in the rat paraventricular nucleus. Auton Neurosci 2001; 88: 52-60.
9. Onaka T, Hamamura M, Yagi K. Potentiation of vasopressin secretion by footshocks in rats. Jpn J Physiol 1986; 36: 1253-60.
10. Onaka T, Serino R, Ueta Y. Intermittent footshock facilitates dendritic vasopressin release but suppresses vasopressin synthesis within the rat supraoptic nucleus. J Neuroendocrinol 2003; 15: 629-32.
11. Whitnall MH, Mezey E, Gainer H. Co-localization of corticotropin-releasing factor and vasopressin in median eminence neurosecretory vesicles. Nature 1985; 317: 248-50.
12. Sawchenko PE, Swanson LW, Vale WW. Co-expression of corticotropin-releasing factor and vasopressin immunoreactivity in parvocellular neurosecretory neurons of the adrenalectomized rat. Proc Natl Acad Sci USA 1984; 81: 1883-87.
13. Mouri T, Itoi K, Takahashi K, Suda T, Murakami O, Yoshinaga K. Colocalization of corticotropin-releasing factor and vasopressin in the paraventricular nucleus of the human hypothalamus. Neuroendocr 1993; 57: 34-39.
14. Wiley MK, Pearlmutter AF, Miller RE. Decreased adrenal sensitivity to ACTH in the vasopressin-deficient (Brattleboro) rat. Neuroendocr 1974; 14: 257-70.
15. Kjaer A, Knigge U, Bach FW, Warberg J. Impaired histamine- and stress-induced secretion of ACTH and beta-endorphin in vasopressin-deficient Brattleboro rats. Neuroendocr 1993; 57: 1035-41.
16. Caffé AR, van Leeuwen FW, Luiten PGM. Vasopressin cells in the medial amygdala of the rat project to the lateral septum and ventral hippocampus. J Comp Neurol 1987; 261: 237-52.
17. De Vries GJ, Bulis RM. The origin of the vasopressinergic and oxytocinergic innervation of the rat brain with special reference to the lateral septum. Brain Res 1983; 273: 307-17.
18. van Leeuwen FW, Caffé AR. Vasopressin-immunoreactive cell bodies in the bed nucleus of the stria terminalis of the rat. Cell Tissue Res 1983; 28: 525-34.
19. Lolait SJ, O'Carroll AM, Mahan LC, Felder CC, Button DC, Young WS, III, Mezey E, Brownstein MJ. Extrapituitary expression of the rat V1b vasopressin receptor gene. Proc Natl Acad Sci USA 1995; 92: 6783-87.
20. Young LJ, Toloczko D, Insel TR. Localization of vasopressin (V1a) receptor binding and mRNA in the rhesus monkey brain. J Neuroendocrinol 1999; 11: 291-97.
21. Vaccari C, Lolait S J, Ostrowski NL. Comparative distribution of vasopressin V1b and oxytocin receptor messenger ribonucleic acids in brain. Endocrinol 1998; 139: 5015-33.
22. Morei A, O'Carroll AM, Brownstein MJ, Lolait SJ. Molecular cloning and expression of a rat Vla arginine vasopressin receptor. Nature 1992; 356: 523-26.
23. 1a receptor antagonist SR-49059 in the rat brain: an in vitro and in vivo autoradiographic study. Neuroendocr 1999; 69:113-20.
24. De Wied D. The influence of posterior and intermediate lobe of the pituitary and pituitary peptides on the maintenance of a conditioned avoidance response in rats. Int J Neuropharmacol 1965; 4: 157-67.
25. De Wied D. Preservation of a conditioned avoidance response by lysine vasopressin. J Endocrinol 1970; 48: xlv-xlvi.
26. Koob GF, Bloom FE. Behavioral effects of neuropeptides: endorphins and vasopressin. Annu Rev Physiol 1982; 44: 571-82.
27. Alescio-Lautier B, Metzger D, Soumireu-Mourat B. Central behavioral effects of vasopressin: point and perspectives. Rev Neurosci 1993; 4: 239-66.
28. Dantzer R, Bluthe RM. Vasopressin involvement in antipyresis, social communication, and social recognition: a synthesis. Crit Rev Neurobiol 1992; 6: 243-55.
29. Engelmann M, Wotjak CT, Neumann I, Ludwig M, Landgraf R. Behavioral consequences of intracerebral vasopressin and oxytocin: focus on learning and memory. Neurosci Biobehav Rev 1996; 20: 341-58.
30. Bhattacharya SK, Bhattacharya A, Chakrabarti A. Anxiogenic activity of intraventricularly administered arginine vasopressin in the rat. Biog Amine 1998; 14: 367-85.
31. Liebsch G, Wotjak CT, Landgraf R, Engelmann M. Septal vasopressin modulates anxiety-related behaviour in rats. Neurosci Lett 1996; 217: 101-04.
32. Landgraf R, Gerstberger R, Montkowski A, Probst JC, Wotjak CT, Holsboer F, et al. V1 vasopressin receptor antisense oligodeoxy-nucleotide into septum reduces vasopressin binding, social discrimination abilities, and anxiety-related behavior in rats. J Neurosci 1995; 15: 4250-58.
33. Stoehr JD, Cheng SW, North WG. Homozygous Brattleboro rats display attenuated conditioned freezing responses. Neurosci Lett 1993; 153: 103-06.
34. Keck ME, Wigger A, Welt T, Muller MB, Gesing A, Reul JM, et al. Vasopressin mediates the response of the combined dexamethasone/CRH test in hyper-anxious rats: implications for pathogenesis of affective disorders. Neuropsychopharmacology 2002; 26: 94-105.
35. Keck ME, Welt T, Müller MB, Uhr M, Ohl F, Wigger A, et al. Reduction of Hypothalamic Vasopressinergic Hyperdrive Contributes to Clinically Relevant Behavioral and Neuroendocrine Effects of Chronic Paroxetine Treatment in a Psychopathological Rat Model. Neuropsychopharmacology 2003; 28: 235-43.
36. Rabadan-Diehl C, Lolait S J, Aguilera G. Regulation of pituitary vasopressin V1b receptor mRNA during stress in the rat. J Neuroendocrinol 1995; 7: 903-10.
37. De Bellis MD, Gold PW, Geracioti TD Jr, Listwak SJ, Kling MA. Association of fluoxetine treatment with reductions in CSF concentrations of corticotropin-releasing hormone and arginine vasopressin in patients with major depression. Am J Psychiatry 1993; 150: 656-57.
38. van Londen L, Goekoop JG, van Kempen GMJ, Frankhuijzen-Sierevogel AC, Wiegant VM, Van der Velde EA, et al. Plasma levels of arginine vasopressin elevated in patients with major depression. Neuropsychopharmacology 1997; 17: 284-92.
39. De Winter RF, Van Hemert AM, DeRijk RH, Zwinderman KH, Frankhuijzen-Sierevogel AC, Wiegant VM, et al. Anxious-retarded depression: relation with plasma vasopressin and cortisol. Neuropsychopharmacology 2003; 28: 140-47.
40. Purba JS, Hoogendijk WJG, Hofman MA, Swaab DF. Increased number of vasopressin- and oxytocin-expressing neurons in the paraventricular nucleus of the hypothalamus in depression. Arch Gen Psychiatry 1996; 53: 137-43.
41. Zhou JN, Riemersma RF, Unmehopa UA, Hoogendijk WJG, van Heerikhuize JJ, Hofman MA, et al. Alterations in arginine vasopressin neurons in the suprachiasmatic nucleus in depression. Arch Gen Psychiatry 2001; 58: 655-62.
42. Abelson JL, Le Mellédo JM, Bichet DG. Dose response of arginine vasopressin to the CCK-B agonist, pentagastrin. Neuropsychopharmacology 2001; 24:161-69.
43. Scott LV, Dinan TG. Vasopressin as a target for antidepressant development: an assessment of the available evidence. J Affect Disord 2002; 72:113-24.
44. Manning M, Sawyer WH. Design, synthesis and some uses of receptor-specific agonists and antagonists of vasopressin and oxytocin. J Recept Res 1993; 13: 195-214.
45. Paranjape SB, Thibonnier M. Development and therapeutic indications of orally-active non-peptide vasopressin receptor antagonists. Expert Opin Invest Drugs 2001; 10: 825-34.
46. Thibonnier M, Coles P, Thibonnier A, Shoham M. The basic and clinical pharmacology of nonpeptide vasopressin receptor antagonists. Annu Rev Pharmacol Toxicol 2001; 41: 175-202.
47. Serradeil-Le Gal C, Wagnon J, Valette G, Garcia G, Pascal M, Maffrand JP, et al. Nonpeptide vasopressin receptor antagonists: development of selective and orally active V1a, V2 and V1b receptor ligands. Prog Brain Res 2002; 139: 197-210.
48. 1b receptor antagonist, SSR149415, suggest a novel approach for the treatment of stress-related disorders. J Neuropsychopharmacol 2002; 5 (Suppl. 1): S128.
49. 1b receptor antagonist, SSR149415, suggest ah innovative approach for the treatment of stress-related disorders. Proc Natl Acad Sci USA 2002; 99: 6370-75.
50. Griebel G, Simiand J, Steinberg R, Serradeil-Le Gal C, Wagnon J, Pascal M, et al. SSR149415, a non-peptide vasopressin V1b receptor antagonist: anxiolytic- and antidepressant-like profiles in rodents. Program No 396 7 Abstract Viewer/Itinerary Planner Washington, DC: Society for Neuroscience, CD-ROM 2002.
51. Griebel G, Simiand J, Stemmelin J, Gal CS, Steinberg R. The vasopressin V1b receptor as a therapeutic target in stress-related disorders. Curr Drug Target CNS Neurol Disord 2003; 2: 191-200.
52. Griebel G, Blanchard DC, Jung A, Blanchard RJ. A model of 'antipredator' defense in Swiss-Webster mice: Effects of benzodiazepine receptor ligands with different intrinsic activities. Behav Pharmacol 1995; 6: 732-45.
53. 1b receptor knockout mice. Neuroscience (submitted) 2003.
54. Molewijk HE, Hartog K, Vanderpoel AM, Mos J, Olivier B. Reduction of guinea pig pup isolation calls by anxiolytic and antidepressant drugs. Psychopharmacology 1996; 128:31-38.
55. Olivier B, Molewijk E, vanOorschot R, vanderHeyden J, Ronken E, Mos J, et al. Rat pup ultrasonic vocalization: effects of benzodiazepine receptor ligands. Eur J Pharmacol 1998; 358:117-28.
56. Cole RL, Sawchenko PE. Neurotransmitter regulation of cellular activation and neuropeptide gene expression in the paraventricular nucleus of the hypothalamus. J Neurosci 2002; 22: 959-69.
57. Holsboer F. The rationale for corticotropin-releasing hormone receptor (CRH-R) antagonists to treat depression and anxiety. J Psychiat Res 1999; 33: 181-214.
58. Steckler T, Holsboer F, Reul JMHM. Glucocorticoids and depression. Best Pract Res Clin Endoc Met 1999; 13: 597-614.
59. Bremner JD, Krystal JH, Southwick SM, Charney DS. Noradrenergic mechanisms in stress and anxiety .1. Preclinical studies. Synapse 1996; 23: 28-38.
60. Bremner JD, Krystal JH, Southwick SM, Charney DS. Noradrenergic mechanisms in stress and anxiety .2. Clinical studies. Synapse 1996; 23: 39-51.
61. Koob GF. Corticotropin-releasing factor, norepinephrine, and stress. Biol Psychiat 1999; 46:1167-80.
62. Funk D, Stewart J. Role of catecholamines in the frontal cortex in the modulation of basal and stress-induced autonomic output in rats. Brain Res 1996; 741: 220-29.
63. Steinberg R, Alonso R, Griebel G, Bert L, Jung M, Oury-Donat F. Selective blockade of neurokinin-2 receptors produces antidepressant-like effects associated with reduced corticotropin-releasing factor function. J Pharmacol Exp Ther 2001; 299: 449-58.
64. 1 receptor antagonist. II. Characterization in rodent models of stress-related disorders. J Pharmacol Exp Ther 2002; 301: 333-45.
65. Porsolt RD, Le Pichon M, Jalfre M. Depression: a new animal model sensitive to antidepressant treatments. Nature 1977; 266: 730-32.
66. Simiand J, Guitard J, Griebel G, Soubrié P. Tonic immobility in gerbils: a new model for detecting antidepressant-like effects. Behav Pharmacol 2003; 14 (Suppl. 1): S40.
67. Steru L, Chermat R, Thierry B, Mico JA, Lenegre A, Steru M, Simon P, Porsolt RD. The automated Tail Suspension Test: a computerized device which differentiates psychotropic drugs. Prog Neuropsychopharmacol Biol Psychiatry 1987; 11: 659-71.
68. Willner P, Muscat R, Papp M. Chronic mild stress-induced anhedonia: a realistic animal model of depression. Neurosci Biobehav Rev 1992; 16: 525-34.
69. Ducottet C, Griebel G, Belzung C. Effects of the selective nonpeptide corticotropin-releasing factor receptor 1 antagonist antalarmin in the chronic mild stress model of depression in mice. Prog Neuropsychopharmacol Biol Psychiatry 2003; 27:625-31.
70. Blanchard DC, Sakai RR, McEwen B, Weiss SM, Blanchard RJ. Subordination stress: Behavioral, brain, and neuroendocrine correlates. Behav Brain Res 1993; 58:113-21.
71. Stemmelin J, Lukovic L, Soubrié P, Griebel G. The antidepressant-like effects of the V1b receptor antagonist SSR149415 in rats are mediated by the lateral septum and the central nucleus of the amygdala. Program No 217 2 Abstract Viewer/Itinerary Planner Washington, DC: Society for Neuroscience 2003.
72. Willner P, Muscat R, Papp M. An animal model of anhedonia. Clin Neuropharmacol 1992; 15 Suppl 1 Pt A: 550A-1A.
73. Alonso R, Griebel G, Pavone G, Stemmelin J, Le Fur G, Soubrié P. Blockade of CRF1 or V-1b receptors reverses stress-induced suppression of neurogenesis in a mouse model of depression. Mol Psychiatr 2004; 9: 278-86.
74. 1 antagonist, SSR125543A in the VBS are suggestive of antidepressant-like activity. Program No 307 3 Abstract Viewer/Itinerary Planner Washington, DC: Society for Neuroscience, CD-ROM 2002.
75. Griebel G, Serradeil-Le Gal C. In: Steckler T, Kalin N, Reul JMHM, Ed., Handbook on Stress, Immunology and Behaviour. The Netherlands (in press), Elsevier Science B.V. 2004.
76. Coccaro EF, Kavoussi RI, Hauger RL, Cooper TB, Ferris CF. Cerebrospinal fluid vasopressin levels - Correlates with aggression and serotonin function in personality-disordered subjects. Arch Gen Psychiatry 1998; 55: 708-14.
77. Ferris CF, Singer EA, Meenan DM, Albers HE. Inhibition of vasopressin-stimulated flank marking behavior by V1-receptor antagonists. Eur J Pharmacol 1988; 154:153-59.
78. Ferris CF, Meenan DM, Axelson JF, Albers HE. A vasopressin antagonist can reverse dominant/subordinate behavior in hamsters. Physiol Behav 1986; 38: 135-38.
79. Ferris CF, Potegal M. Vasopressin receptor blockade in the anterior hypothalamus suppresses aggression in hamsters. Physiol Behav 1988; 44: 235-39.
80. Ferris CF, Delville Y. Vasopressin and serotonin interactions in the control of agonistic behavior. Psychoneuroendocr 1994; 19: 593-601.
81. Wersinger SR, Ginns EI, O'Carrol AM, Lolait SJ, Young WS. Vasopressin V1b receptor knockout reduces aggressive behavior in male mice. Mol Psychiatr 2002; 7: 975-84.
82. Van Wimersma Greidanus TB, Van Ree JM, De Wied D. Vasopressin and memory. Pharmacol Ther 1983; 20: 437-58.
83. Hernando F, Schoots O, Lolait SJ, Burbach JPH. Immunohistochemical localization of the vasopressin V1b receptor in the rat brain and pituitary gland: Anatomical support for its involvement in the central effects of vasopressin. Endocrinol 2001; 142: 1659-68.
84. Orcel H, Tobin VA, Alonso G, Rabie A. Immunocytochemical localization of vasopressin v1a receptors in the rat pituitary gonadotropes. Endocrinol 2002; 143: 4385-88.
85. Pacher P, Kecskemeti V. Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns? Curr Pharm Design 2004; 10(20): 2463-75.
86. Tsang SY, Xue H. Development of effective therapeutics targeting the GABAA receptor: naturally occurring alternatives. Curr Pharm Design 2004; 10(9): 1035-44.
87. Yoshikawa M, Takahashi M, Yang S. Delta opioid peptides derived from plant proteins. Curr Pharm Design 2003; 9(16): 1325-30.